CTOs on the Move

BioSkryb

www.bioskryb.com

 
Bioskryb is a venture-backed startup bringing new solutions for cellular heterogeneity, in both the research and clinical space studies, using a proprietary genome amplification system.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioSkryb raised $11.5M on 01/08/2020

Similar Companies

Elixirgen Therapeutics

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines

Abnova Corporation

Abnova Corporation is a Walnut, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspen Neuroscience

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson`s disease (PD) and extending across the brain and affected organs.

BlueWillow Biologics

NanoBio® is a division of BlueWillow Biologics, Inc., a privately-held biopharmaceutical company focused on developing intranasal vaccines and topical anti-infective therapies based on its patented nanotechnology platform.

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.